Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 Clinical trials 2 References

Motexafin lutetium

●Српски / srpski ●Srpskohrvatski / српскохрватски Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Motexafin lutetium
Names

Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number	246252-04-0^Y
3D model (JSmol)	Interactive image
PubChem CID	3081907
UNII	0V38NF6N89^Y
SMILES CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
Chemical formula	C₅₂H₇₂LuN₅O₁₄
Molar mass	1166.136 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is ^YN ?) Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).^[1]

It is photoactivated by 732 nm light which allows greater depth of penetration.^[2]

Clinical trials[edit]

Phase II clinical trials were in progress in 1999.^[3]

A phase I trial for prostate cancer reported in 2009.^[4]

References[edit]

^ Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine, 2002

^ http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T

^ Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Archived 2012-07-13 at archive.today, 1999

^ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.

Lutetium compounds

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Motexafin_lutetium&oldid=1093497878" Categories: ●Tetrapyrroles ●Lutetium complexes ●Dermatologic drug stubs Hidden categories: ●Webarchive template wayback links ●Webarchive template archiveis links ●Articles without InChI source ●Chemical pages without ChemSpiderID ●Articles without EBI source ●Articles without KEGG source ●Articles containing unverified chemical infoboxes ●Chembox image size set ●Articles with short description ●Short description matches Wikidata ●All stub articles ●This page was last edited on 17 June 2022, at 00:37 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view